



06-17-02

Gp/1632  
Docket No. 2026-4231US3

TECH CENTER 1600/2900  
JUN 24 2002

RECEIVED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Chamberlain, R. et al.

Group Art Unit: 1632

Serial No.: 09/838,987

Examiner: Michael C. Wilson

Filed: April 20, 2001

For: HETEROLOGOUS BOOSTING IMMUNIZATIONS

**EXPRESS MAIL CERTIFICATE**

Express Mail Label No.: **EV 094904047 US**

Date of Deposit: **June 14, 2002**


I hereby certify that the following attached paper(s) and/or fee

1. Response to Official Action Pursuant to 37 C.F.R. §1.111 (15 pages), and
2. Return Receipt Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, DC 20231, Box Non-Fee Amendment

Jafet N. Cotto

(Typed or printed name of person mailing papers(s) and/or fee)

  
(Signature of person mailing paper(s) and/or fee)

**Correspondence Address:**

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053  
(212) 758-4800 Telephone  
(212) 751-6849 Facsimile



RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

#6B  
Dla  
6/26/02

PATENT  
Docket No. 2026-4231US3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Chamberlain R., et al. Group Art Unit : 1633  
Serial No. : 09/838,987 Examiner : Wilson, M.  
Filed : April 20, 2001  
For : HETEROLOGOUS BOOSTING IMMUNIZATIONS

RESPONSE TO OFFICIAL ACTION PURSUANT TO 37 C.F.R. §1.111

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the PTO Official Action mailed March 14, 2002, applicants present the following amendments and remarks.

IN THE CLAIMS

Please amend the following claims:

1. (Twice amended) A method for immunizing a mammal against an antigen-associated disease inducing an effective immunological response against at least one antigen in the mammal using heterologous boosting immunization, said method comprising the steps of:  
- inoculating the mammal with a first recombinant vector comprising a DNA vector and a nucleic acid encoding said antigen; and